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Ensuring patient safety around high-risk medications such as oral anticoagulants is a global 
challenge. Several patient-focused interventions have been used to support vulnerable patients 
such as older persons taking oral anticoagulants. However, limited research has been done to 
support those with limited health literacy, and those from cultural and linguistic diverse 
(CALD) backgrounds. 
 
Qualitative and quantitative methods were used to identify the limitations in health literacy, 
warfarin knowledge gaps, patient’s and carer’s needs and preferences for medicine information 
about oral anticoagulants. 
 
A double-sided A4 size Warfarin action Plan leaflet was developed, and feedback was 
obtained from patients and their carers. Several benefits of the action plan were highlighted 
such as its concise format and understandable content, the use of visuals and how it was 
interactive. The action plan also addressed the knowledge gaps of patients and carers who had 
been using warfarin for several years, highlighting the need for regular follow up and 
education. An unexpected finding was that the WAP had a positive impact on behaviour. 
 
Based on the findings from the feedback on the WAP leaflet and knowledge gaps about 
NOACs, web-based education materials were assessed to see if they would also have a similar 
benefit in terms of understandability and actionability. The majority of materials were 
understandable, however, were not actionable. These findings suggest that there is a need for 
high quality NOAC medicines information that are actionable. 
 
Overall, this thesis highlights the beneficial role of the written WAP leaflet in supporting older 
persons taking oral anticoagulants and their carers. The implications of this leaflet is that it 
could also be used for NOACs and be provided to patients and their carers in a variety of 
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Medication safety is defined as freedom from preventable harm with medication use (ISMP 
Canada, 2007). 
 
People-centred care refers to an approach to care that consciously adopts the perspectives of 
individuals, carers, families and communities as participants in, and beneficiaries of, trusted 
health systems that are organised around the comprehensive needs of people rather than 
individual diseases, and respects social preferences. People-centred care also requires that 
patients receive the education and support they need to make decisions and to participate in their 
own care. Patient- and person-centred care should encompass both clinical encounters as well as 
attention to the health of people in their community and their crucial role in shaping policy and 
health services (World Health Organization Sixty-ninth world health assembly 2016). 
 
Patient-centred care (the more widely used term) refers to the provision of care that is respectful 
of, and responsive to, individual patient preferences, needs and values, and that ensures that the 
patient’s values guide all clinical decisions (Institute of Medicine 2001) 
 
Person-centred care is a model in which healthcare systems are encouraged to partner with 
patients to co-design and deliver personalised care that provides people with the high-quality 
care they need and to improve healthcare system efficiency and effectiveness (Santana et al. 
2018). Person-centred care is respectful of, and responsive to, the preferences, needs and values of 
patients and consumers. Key dimensions of person-centred care include respect, emotional
 
xi 
support, physical comfort, information and communication, continuity and transition, care 
coordination, involvement of carers and family, and access to care (Australian Commission on 
Safety and Quality in Health Care 2011). This is also known as patient-centred care or consumer-
centred care (Australian Commission on Safety and Quality in Health Care (ACSQHC) 2017). 
 
Consumer-centred care refers to the provision of care that is easy for patients to obtain when 
they need it and ensures that healthcare staff respect and respond to patient choices, needs and 
values. Partnerships are formed between patients, their family, carers and healthcare providers 
(Australian Commission on Safety and Quality in Health Care 2010). 
 
Medication incidents refers to problems that occur in the prescription, dispensing and 
administration of medications (Roughead & Semple 2009). 
 
Adverse drug events are defined as the proportion of medication incidents that result in patient 
harm (Roughead & Semple 2009) 
 
High-alert medications are drugs that confer a heightened risk of causing significant patient 
harm when they are used inappropriately. Although mistakes may or may not be more common 
with these drugs, the consequences of an error are clearly more devastating to patients (Institute for 
Safe Medication Practices (ISMP) 2014). 
 
Older persons are defined here as persons aged 65 years and older (Orimo et al. 2006; World 
Health Organization 2018a). 
 
xii 
Limited health literacy is defined by the WHO as “the cognitive and social skills which 
determine the motivation and ability of individuals to gain access to, understand and use 
information in ways which promote and maintain good health” (World Health Organization 
2018b). 
 
Culturally and linguistically diverse (CALD) is defined in Australia as those people born 
overseas, in countries other than those classified by the Australian Bureau of Statistics as “main 
English-speaking countries”. The term CALD is also referred to as ‘ethnic minorities’ 
(Alhomoud et al. 2013; Mohammad, Saini & Chaar 2015), ‘multicultural’, ‘migrants’ and ‘from 
a non-English speaking background (Smith V and Schaffer E. 2014). 
